MSH2 and pancreatic adenocarcinoma: According to Figure 3(a) high expression of MSH2 was associated with poorer prognosis in ACC, BLCA, KICH, KIRP, LGG, LIHC, MESO, PAAD, SARC, and UCEC, while low expression of MSH2 was associated with poorer prognosis in KIRC, READ, and THYM.